newsfilter
← Latest News
GlobeNewswire·

X4 Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Company's strategic focus and highest priority is now the advancement of the 4WARD Phase 3 chronic neutropenia trialPreviously announced workforce reductions resulted in $13M annualized cost savingsSuccessful completion